Digestive processes: Methanobrevibacter smithii is involved in the digestion of dietary carbohydrates in the human gut. It consumes hydrogen produced by other microorganisms during the fermentation of complex carbohydrates and uses it to produce methane. This process helps regulate the microbial ecosystem in the gut and influences the efficiency of energy extraction from the diet.
Association with obesity: Some studies have suggested an association between the abundance of Methanobrevibacter smithii in the gut microbiota and obesity. Methane production by Methanobrevibacter smithii may influence energy metabolism and contribute to increased energy harvest from the diet. However, the exact mechanisms underlying this association and whether Methanobrevibacter smithii directly contributes to obesity or is simply a marker of dysbiosis are still under investigation.
Inflammatory bowel disease (IBD): Methanobrevibacter smithii has been detected in the gut microbiota of individuals with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. However, its role in the pathogenesis of IBD is not fully understood. Some studies have suggested that methane production by Methanobrevibacter smithii may have anti-inflammatory effects in the gut, while others have proposed that it may exacerbate intestinal inflammation by altering microbial interactions.
Hydrogen disposal: Methanobrevibacter smithii plays a role in hydrogen disposal in the gut by consuming hydrogen produced during microbial fermentation. In conditions where excess hydrogen accumulates in the gut, such as small intestinal bacterial overgrowth (SIBO), methane production by Methanobrevibacter smithii may help alleviate symptoms associated with hydrogen accumulation, such as bloating and abdominal discomfort.
Potential therapeutic target: Given its abundance and potential role in gut health and disease, Methanobrevibacter smithii has been proposed as a potential therapeutic target for modulating the gut microbiota. Strategies aimed at selectively targeting Methanobrevibacter smithii, such as antimicrobial treatments or dietary interventions, are being investigated for their potential to modulate methane production and improve gastrointestinal health.
Methanobrevibacter smithii impacts on other bacteria of the same rank
Other bacteria of the same rank impacting Methanobrevibacter smithii
This is an Academic site. It generates
theoretical models
of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some
hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [216.73.216 ]
